Hims & Hers Health (HIMS) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Hims & Hers Health (HIMS) right now is Recurring subscription model: Hims is built on auto-refilling monthly subscriptions rather than one-time sales, which produces predictable, compounding revenue as the base grows. Revenue (TTM) is ~$2.37 billion. If that keeps playing out, the setup is favourable; the risk to it is the GLP-1 category is the clearest risk: the shift from cheaper compounded semaglutide to branded resale, plus ongoing FDA scrutiny of telehealth compounding and marketing claims, can pressure both growth and gross margins, which compressed sharply to around 65 percent in early 2026. No one can predict where HIMS trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Hims & Hers Health (HIMS) higher?
Recurring subscription model
Hims is built on auto-refilling monthly subscriptions rather than one-time sales, which produces predictable, compounding revenue as the base grows. Subscribers reached roughly 2.6 million in the first quarter of 2026, up about 9 percent year over year. A larger base of retained subscribers, each potentially buying more categories over time, is the core engine the bull case relies on.
Category expansion beyond the original niche
The platform started in men's sexual health and hair loss but has pushed into dermatology, mental health, women's health, weight management, and longevity-adjacent offerings. Each new condition is a chance to cross-sell existing subscribers and acquire new ones. Management has set long-range targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, which depends on this broadening working.
Vertical integration and personalization
Hims has invested in affiliated pharmacies, a lab, and peptide manufacturing to control more of its supply chain and offer personalized formulations. Owning these capabilities can support differentiated products and, over time, better unit economics. The company frames personalization as a moat that generic telehealth and pharmacy competitors struggle to copy quickly.
Branded GLP-1 partnership reset
After the 2026 conflict with Novo Nordisk, Hims now offers branded semaglutide products on its platform and has dialed back compounded GLP-1 marketing. This removes a major legal overhang and keeps Hims inside the high-demand weight-loss category. The trade-off is that reselling branded drugs typically carries thinner margins than the compounded products it sold before.
What could weigh on HIMS?
The GLP-1 category is the clearest risk: the shift from cheaper compounded semaglutide to branded resale, plus ongoing FDA scrutiny of telehealth compounding and marketing claims, can pressure both growth and gross margins, which compressed sharply to around 65 percent in early 2026. Competition is intense and well funded, including Ro, LifeMD, Teladoc, and numerous smaller GLP-1 telehealth providers, which can raise customer-acquisition costs. Growth decelerated to roughly 4 percent year over year in the first quarter of 2026 even as the valuation stayed rich relative to current profitability, so any further slowdown or margin erosion could weigh on the stock. The company also carries dependence on a few high-demand categories and on continued heavy marketing spend.
How to think about a HIMS forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the HIMS guide and whether HIMS is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the HIMS outlook
The bottom line: what is driving Hims & Hers Health (HIMS) is Recurring subscription model, with revenue (ttm) at ~$2.37 billion. If that keeps playing out the setup is favourable; the risk is the GLP-1 category is the clearest risk: the shift from cheaper compounded semaglutide to branded resale, plus ongoing FDA scrutiny of telehealth compounding and marketing claims, can pressure both growth and gross margins, which compressed sharply to around 65 percent in early 2026. No one can predict the price, so treat any HIMS forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around HIMS with Walnut
Use Hims & Hers Health as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Hims & Hers Health (HIMS)?
+
No one can reliably predict where HIMS will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Hims & Hers Health higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive HIMS higher?
+
The main growth drivers are Recurring subscription model; Category expansion beyond the original niche; Vertical integration and personalization. Whether they play out is the real question, not a guaranteed path.
What are the risks to HIMS?
+
The GLP-1 category is the clearest risk: the shift from cheaper compounded semaglutide to branded resale, plus ongoing FDA scrutiny of telehealth compounding and marketing claims, can pressure both growth and gross margins, which compressed sharply to around 65 percent in early 2026. Competition is intense and well funded, including Ro, LifeMD, Teladoc, and numerous smaller GLP-1 telehealth providers, which can raise customer-acquisition costs. Growth decelerated to roughly 4 percent year over year in the first quarter of 2026 even as the valuation stayed rich relative to current profitability, so any further slowdown or margin erosion could weigh on the stock. The company also carries dependence on a few high-demand categories and on continued heavy marketing spend.
Will HIMS stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Hims & Hers Health's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is HIMS a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the HIMS "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.